Table 3.
FDA-approved exosomes in clinical trials for the treatment of pancreatic cancer
| NCT number | Title | Status | Conditions | Interventions | Phases |
|---|---|---|---|---|---|
| NCT03821909 | Acquisition of Portal Venous CTCs and Exosomes From Patients With Pancreatic Cancer by EUS | Unknown status | Pancreatic Cancer | Procedure: Endoscopic ultrasound-guided protal venous blood sampling | |
| NCT02393703 | Interrogation of Exosome-mediated Intercellular Signaling in Patients With Pancreatic Cancer | Recruiting | Pancreatic Cancer|Benign Pancreatic Disease | ||
| NCT03608631 | iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation | Recruiting | KRAS NP_004976.2:p.G12D|Metastatic Pancreatic Adenocarcinoma|Pancreatic Ductal Adenocarcinoma|Stage IV Pancreatic Cancer AJCC v8 | Drug: Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA | Phase 1 |
| NCT03032913 | Diagnostic Accuracy of Circulating Tumor Cells (CTCs) and Onco-exosome Quantification in the Diagnosis of Pancreatic Cancer—PANC-CTC | Completed | Pancreatic Ductal Adenocarcinoma (PDAC) | Pancreatic Ductal Adenocarcinoma (PDAC) | |
| NCT03711890 | Ultra-High Resolution Optical Coherence Tomography in Detecting Micrometer Sized Early Stage Pancreatic Cancer in Participants With Pancreatic Cancer | Recruiting | Pancreatic Carcinoma|Pancreatic Intraductal Papillary Mucinous Neoplasm, Pancreatobiliary-Type | Procedure: Optical Coherence Tomography|Procedure: Therapeutic Conventional Surgery|Diagnostic Test: Laboratory Evaluation | Not Applicable |
| NCT03791073 | New Biomarkers in Pancreatic Cancer Using EXPEL Concept | Active, not recruiting | Oncology | ||
| NCT03250078 | A Pancreatic Cancer Screening Study in Hereditary High Risk Individuals | Recruiting | Pancreatic Neoplasms | Diagnostic Test: MRI/MRCP | |
| NCT04636788 | Circulating Extracellular Exosomal Small RNA as Potential Biomarker for Human Pancreatic Cancer | Recruiting | Pancreas Adenocarcinoma | Procedure: Venous sampling | Not Applicable |
| NCT03410030 | Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) | Recruiting | Pancreatic Cancer|Pancreas Cancer|Pancreatic Adenocarcinoma Resectable|Pancreatic Ductal Adenocarcinoma|Pancreas Metastases | Drug: Ascorbic Acid|Drug: Paclitaxel protein-bound|Drug: Cisplatin|Drug: Gemcitabine | Phase 1|Phase 2 |
| NCT03334708 | A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma | Recruiting | Pancreatic Cancer|Pancreatic Diseases|Pancreatitis|Pancreatic Cyst | Diagnostic Test: Blood Draw|Diagnostic Test: Tumor Tissue Collection|Diagnostic Test: Cyst Fluid |